Blog
RSS FeedPosted by Michael Wonder on 07 Apr 2022
NICE says new triple negative advanced breast cancer drug too expensive for NHS use
7 April 2022 - NICE has today issued draft guidance which does not recommend sacituzumab govitecan for treating locally advanced or ...
Posted by Michael Wonder on 07 Apr 2022
Hundreds of people with some forms of urothelial cancer to receive new treatment
7 April 2022 - Over 800 people with locally advanced or metastatic urothelial cancer are set to benefit from a new ...
Posted by Michael Wonder on 30 Mar 2022
Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm
30 March 2022 - Tagraxofusp is human interleukin-3 genetically conjugated to diphtheria toxin protein. ...
Posted by Michael Wonder on 24 Mar 2022
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
24 March 2022 - NICE has published evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated advanced renal cell ...
Posted by Michael Wonder on 23 Mar 2022
Acceptability of manufacturer proposed utility values for NICE cancer medicine appraisals: analysis of manufacturers’ information sources
21 March 2022 - The NICE method guide for technology appraisals encourages medicine manufacturers to use the EuroQol 5 Dimension in ...
Posted by Michael Wonder on 20 Mar 2022
NHS fast tracks new ‘gamechanging’ drug for lung cancer
18 March 2022 - A targeted new drug for a rare and aggressive form of lung cancer will be fast-tracked ...
Posted by Michael Wonder on 16 Mar 2022
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
16 March 2022 - NICE has published evidence-based recommendations on the use of dostarlimab (Jemperli) for the treatment of adults ...
Posted by Michael Wonder on 16 Mar 2022
Life-extending injection for blood cancer available on the NHS
15 March 2022 - A life-extending injection for a fatal form of blood cancer will be available to around 350 ...
Posted by Michael Wonder on 09 Mar 2022
NICE unable to provide guidance on a new use of lenalidomide
9 March 2022 - NICE is unable to make a recommendation on the use of lenalidomide for the treatment of patients ...
Posted by Michael Wonder on 08 Mar 2022
NICE yet to support the use of pralsetinib on the NHS
3 March 2022 - NICE publishes appraisal consultation document for a new medicine for certain patients with non-small-cell lung cancer. ...
Posted by Michael Wonder on 08 Mar 2022
NICE draft guidance does not recommend pembrolizumab plus chemotherapy for triple negative breast cancer
8 March 2022 - The evidence showed that pembrolizumab plus chemotherapy is more effective than paclitaxel or nab-paclitaxel, although the ...
Posted by Michael Wonder on 04 Mar 2022
Hundreds of patients to benefit from revolutionary lung cancer drug on the NHS
3 March 2022 - A revolutionary targeted drug for lung cancer will be made available to anyone who is eligible, ...
Posted by Michael Wonder on 03 Mar 2022
Over 500 people a year can access a new life extending lung cancer treatment after NICE recommends its use within the Cancer Drugs Fund
3 March 2022 - An innovative life-extending drug for treating mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults ...
Posted by Michael Wonder on 25 Feb 2022
NICE draft guidance recommends tucatinib for advanced breast cancer
25 February 2022 - Taken as two 150 mg tablets twice daily together with anti-cancer medicines trastuzumab and capecitabine, tucatinib ...
Posted by Michael Wonder on 24 Feb 2022
Once a day capsule for people with some forms of ovarian, fallopian tube and peritoneal cancer recommended for routine use in the NHS
24 February 2022 - The 20th cancer treatment to go through the Cancer Drugs Fund following a period of managed access ...